ReachMD

ReachMD CME

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Vizitează neapărat site-ul podcastului și susține-i creatorul: reachmd.com

Autor

ReachMD

Categorie

Science

Site-ul podcastului

reachmd.com

Cel mai nou episod

20 oct. 2026

Unde asculți?

Podcasturi în aplicație Replaio Radio În curând

Podcasturile ajung în curând în aplicație. Instaleaz-o acum și fii primul care descoperă o abordare complet nouă a podcasturilor

Descarcă din Google Play Instalează gratuit Android 10 mil.+ descărcări · nota 4,7+ iOS în curând

Episoade

Should We Look for Gout in the Cardiology Clinic? 24.10.2023

Claim your CME credit at https://reachmd.com/programs/cme/should-we-look-for-gout-in-the-cardiology-clinic/15964/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate...

What Are the Emerging Therapies for Managing Gout? 24.10.2023

Claim your CME credit at https://reachmd.com/programs/cme/what-are-the-emerging-therapies-for-managing-gout/15963/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate...

What’s New About Gout? Rheumatology Perspective 24.10.2023

Claim your CME credit at https://reachmd.com/programs/cme/whats-new-about-gout-rheumatology-perspective/15962/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate bur...

What’s New About Gout? Nephrology Perspective 24.10.2023

Claim your CME credit at https://reachmd.com/programs/cme/whats-new-about-gout-nephrology-perspective/15961/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burde...

Can You Manage Patients With Uncontrolled Gout More Effectively? 24.10.2023

Claim your CME credit at https://reachmd.com/programs/cme/can-you-manage-patients-with-uncontrolled-gout-more-effectively/15960/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to i...

Treat or Refer: Who Is Responsible for Managing Gout? 24.10.2023

Claim your CME credit at https://reachmd.com/programs/cme/treat-or-refer-who-is-responsible-for-managing-gout/15959/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased ura...

Center of the Target: Which Patients Are Most Likely to Develop Gout? 24.10.2023

Claim your CME credit at https://reachmd.com/programs/cme/center-of-the-target-which-patients-are-most-likely-to-develop-gout/15958/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead...

Is Managing Gout in the Nephrology Clinic a Challenge? 24.10.2023

Claim your CME credit at https://reachmd.com/programs/cme/is-managing-gout-in-the-nephrology-clinic-a-challenge/15957/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased u...

Is Gout Hiding in the Nephrology Clinic? 24.10.2023

Claim your CME credit at https://reachmd.com/programs/cme/is-gout-hiding-in-the-nephrology-clinic/15956/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden an...

Gout Beyond the Joints: What’s the Hidden Danger? 24.10.2023

Claim your CME credit at https://reachmd.com/programs/cme/gout-beyond-the-joints-whats-the-hidden-danger/15955/ This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate bu...

Expert Answers to Common Questions About MET Exon 14–Skipping Mutations in NSCLC 28.12.2022

CME credits: 0.25 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-to-common-questions-about-met-exon-14skipping-mutations-in-nsclc/14678/ Non-small cell lung cancer (NSCLC) is a highly heterogeneous disease, and research has evolved its diagnosis and treatment through the discovery of genetic alterations and molecular pathways, personalizing treatment based on tumor mutati...

Improved Outcomes in mCRPC with PSMA-Directed Diagnostics and Therapies 31.08.2022

CME credits: 1.00 Claim your CME credit at https://reachmd.com/programs/cme/improved-outcomes-in-mcrpc-with-psma-directed-diagnostics-and-therapies/13789/ Prostate-specific membrane antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical features predict different stages of PC progression, the a...

Evolving Perspectives in PIK3CA-related Overgrowth Spectrum Diagnosis & Treatment 26.08.2022

CME credits: 0.50 Claim your CME credit at https://reachmd.com/programs/cme/evolving-perspectives-in-pik3ca-related-overgrowth-spectrum-diagnosis-treatment/13790/ PIK3CA-related overgrowth spectrum (PROS) refers to various clinical entities that share the same pathogenetic mechanism. These disorders are caused by somatic gain-of-function PIK3CA mutations. Diagnosis of PROS is often challenging and...

Optimizing the Care and Quality of Life for Patients with ADPKD – Part 4: Emerging Therapies 31.08.2021

CME credits: 0.50 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-the-care-and-quality-of-life-for-patients-with-adpkd-part-4-emerging-therapies/12680/ This Expert Exchange webcast aims to improve clinicians’ awareness of emerging agents in the treatment of patients with ADPKD. =

A Novel Therapeutic Approach in Myeloid Malignancies: Targeting the Neddylation Pathway 31.08.2021

CME credits: 0.50 Claim your CME credit at https://reachmd.com/programs/cme/a-novel-therapeutic-approach-in-myeloid-malignancies-targeting-the-neddylation-pathway/11694/ Please note: This activity is no longer available for continuing education credit. There is a lack of available therapeutic options for the management of patients with myeloid malignancies, including myelodysplastic syndromes (MDS...

Optimizing the Care and Quality of Life for Patients with ADPKD – Part 3: Management 16.08.2021

CME credits: 0.50 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-the-care-and-quality-of-life-for-patients-with-adpkd-part-3-management/12679/ This Expert Exchange webcast aims to improve clinicians’ ability to manage patients diagnosed with ADPKD. =

Optimizing the Care and Quality of Life for Patients with ADPKD – Part 2: Progression and Prognostication 05.08.2021

CME credits: 0.50 Claim your CME credit at https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12678/ This Expert Exchange webcast aims to improve clinicians’ ability to properly monitor disease progression and make treatment decisions based on prognostic indicators. =

Optimizing the Care and Quality of Life for Patients with ADPKD – Part 1: Detection and Diagnosis 04.08.2021

CME credits: 0.50 Claim your CME credit at https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12677/ This Expert Exchange webcast aims to improve clinicians’ ability to detect and diagnose ADPKD in at-risk patients. =

The Clinical Significance of Imaging in the Management of ADPKD 28.06.2021

CME credits: 0.75 Claim your CME credit at https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12675/ This Expert Exchange webcast aims to better define the importance radiological imaging plays in the management of patients with autosomal dominant polycystic kidney disease (ADPKD). =

Expert Answers to Common Questions for the Management of Hemophilia A 11.07.2019

CME credits: 0.50 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-common-questions-management-hemophilia/10839/ Hemophilia A is a rare bleeding disorder caused by deficiency of clotting factor VIII. The current standard of care for patients with severe hemophilia A centers on replacement therapy with factor VIII concentrate, either on demand when bleeding occurs or prophyl...

Ascultă podcastul ReachMD CME în Replaio

Radio și podcasturi într-o singură aplicație - gratuit și fără înregistrare. Instaleaz-o azi și nu rata lansarea

Descarcă din Google Play

Replaio nu este editorul podcasturilor; numele emisiunilor, coperțile și materialul audio aparțin autorilor lor și sunt distribuite prin fluxuri RSS publice